DK1397124T3 - Anvendelse af diabetesmidler til fremstilling af et lægemiddel med helende virkning - Google Patents

Anvendelse af diabetesmidler til fremstilling af et lægemiddel med helende virkning

Info

Publication number: DK1397124T3
Authority: DK; Denmark
Prior art keywords: medicament; manufacture; healing effect; diabetic agents; insulin
Prior art date: 2001-06-20

Application number

DK02748965T

Other languages

English (en)

Inventor

Philippe Briet

Original Assignee

Merck Sante Sas

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-06-20

Filing date

2002-06-19

Publication date

2007-04-02

2001-06-20 Priority claimed from FR0108130A external-priority patent/FR2826278B1/fr

2002-06-19 Application filed by Merck Sante Sas filed Critical Merck Sante Sas

2007-04-02 Application granted granted Critical

2007-04-02 Publication of DK1397124T3 publication Critical patent/DK1397124T3/da

Links

239000003795 chemical substances by application Substances 0.000 title abstract 2
239000003814 drug Substances 0.000 title abstract 2
206010012601 diabetes mellitus Diseases 0.000 title 1
230000035876 healing Effects 0.000 title 1
238000004519 manufacturing process Methods 0.000 title 1
239000003112 inhibitor Substances 0.000 abstract 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 2
SWLAMJPTOQZTAE-UHFFFAOYSA-N 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(C(O)=O)C=C1 SWLAMJPTOQZTAE-UHFFFAOYSA-N 0.000 abstract 1
102000004366 Glucosidases Human genes 0.000 abstract 1
108010056771 Glucosidases Proteins 0.000 abstract 1
102000004877 Insulin Human genes 0.000 abstract 1
108090001061 Insulin Proteins 0.000 abstract 1
206010022489 Insulin Resistance Diseases 0.000 abstract 1
229940124754 PPAR-alpha/gamma agonist Drugs 0.000 abstract 1
229940123464 Thiazolidinedione Drugs 0.000 abstract 1
230000003178 anti-diabetic effect Effects 0.000 abstract 1
239000003472 antidiabetic agent Substances 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
230000002708 enhancing effect Effects 0.000 abstract 1
229940125396 insulin Drugs 0.000 abstract 1
230000003914 insulin secretion Effects 0.000 abstract 1
229950004994 meglitinide Drugs 0.000 abstract 1
GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 abstract 1
230000000638 stimulation Effects 0.000 abstract 1
150000001467 thiazolidinediones Chemical class 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
General Chemical & Material Sciences (AREA)
Endocrinology (AREA)
Dermatology (AREA)
Chemical Kinetics & Catalysis (AREA)
Zoology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Diabetes (AREA)
Molecular Biology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines Containing Plant Substances (AREA)

DK02748965T 2001-06-20 2002-06-19 Anvendelse af diabetesmidler til fremstilling af et lægemiddel med helende virkning DK1397124T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US29919601P	2001-06-20	2001-06-20
FR0108130A FR2826278B1 (fr)	2001-06-20	2001-06-20	Utilisation d'agents antidiabetiques pour fabriquer un medicament ayant un effet cicatrisant
PCT/FR2002/002124 WO2003003971A2 (fr)	2001-06-20	2002-06-19	Utilisation d'agents antidiabetiques pour fabriquer un medicament ayant un effet cicatrisant

Publications (1)

Publication Number	Publication Date
DK1397124T3 true DK1397124T3 (da)	2007-04-02

Family

ID=26213059

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK02748965T DK1397124T3 (da)	2001-06-20	2002-06-19	Anvendelse af diabetesmidler til fremstilling af et lægemiddel med helende virkning

Country Status (8)

Country	Link
EP (1)	EP1397124B1 (da)
AT (1)	ATE346601T1 (da)
AU (1)	AU2002319381A1 (da)
CY (1)	CY1105822T1 (da)
DE (1)	DE60216453T2 (da)
DK (1)	DK1397124T3 (da)
ES (1)	ES2275889T3 (da)
WO (1)	WO2003003971A2 (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2686899B1 (fr)	1992-01-31	1995-09-01	Rhone Poulenc Rorer Sa	Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
EP2206720A1 (en)	2000-04-12	2010-07-14	Human Genome Sciences, Inc.	Albumin fusion proteins
EP2261250B1 (en)	2001-12-21	2015-07-01	Human Genome Sciences, Inc.	GCSF-Albumin fusion proteins
DE10214506A1 (de) *	2002-04-02	2003-10-16	Beiersdorf Ag	Verwendung von Desoxynojirimycin und dessen Derivaten zur Behandlung und Prophylaxe degenerativer Hautzustände
CA2513213C (en)	2003-01-22	2013-07-30	Human Genome Sciences, Inc.	Albumin fusion proteins
GB0303600D0 (en) *	2003-02-17	2003-03-19	Glaxo Group Ltd	Novel therapeutic method and compositions

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3072527A (en) *	1959-07-01	1963-01-08	Horner Frank W Ltd	Use of tolbutamide in the treatment of acne
DE2401450A1 (de) *	1973-01-16	1974-07-18	John James Voorhees	Pharmazeutische zusammensetzung zur linderung von hautproliferationserkrankungen
US4131652A (en) *	1977-06-22	1978-12-26	Deluccia Charles R	Medicinal skin cream for psoriasis and method
US5145679A (en) *	1989-10-05	1992-09-08	Hinson Joan B	Topical emollient for prevention and treatment of circulatory induced lesions
WO1993008815A1 (en) *	1991-10-28	1993-05-13	Cytoven	Pharmaceutical dipeptide compositions and methods of use thereof
GB9701374D0 (en) *	1997-01-23	1997-03-12	Univ Liverpool	Purinergic agonists and antagonists
US5929055A (en) *	1997-06-23	1999-07-27	The Research Foundation Of State University Of New York	Therapeutic method for management of diabetes mellitus
JP2000212191A (ja) *	1999-01-26	2000-08-02	Sankyo Co Ltd	リン酸誘導体
AR028299A1 (es) *	1999-09-17	2003-05-07	Novartis Ag	Una composicion farmaceutica que comprende nateglinida, un proceso para su preparacion y el uso de dicha composicion para la preparacion de un medicamento para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con diabetes.
AU1133901A (en) *	1999-10-08	2001-04-23	Novartis Ag	Method of treating metabolic disorders
FR2802814B1 (fr) *	1999-12-23	2002-02-22	Aventis Pharma Sa	Association de deoxyfructosazine et d'un antidiabetique de la famille des sulfonylurees
JP2003530156A (ja) *	2000-04-06	2003-10-14	ユニバーシティライセンスホールディングスインコーポレイテッド	創傷治癒を促進するための組成物および方法
PE20020323A1 (es) *	2000-08-22	2002-06-13	Novartis Ag	COMPOSICION FARMACEUTICA QUE COMPRENDE UN POTENCIADOR DE LA SECRESION DE INSULINA E INHIBIDORES DE HMG-Co-A-REDUCTASA O INHIBIDORES DE LA ENZIMA CONVERTIDORA DE ANGIOTENSINA (ACE)

2002
- 2002-06-19 DE DE60216453T patent/DE60216453T2/de not_active Expired - Lifetime
- 2002-06-19 AU AU2002319381A patent/AU2002319381A1/en not_active Abandoned
- 2002-06-19 ES ES02748965T patent/ES2275889T3/es not_active Expired - Lifetime
- 2002-06-19 AT AT02748965T patent/ATE346601T1/de active
- 2002-06-19 WO PCT/FR2002/002124 patent/WO2003003971A2/fr not_active Ceased
- 2002-06-19 EP EP02748965A patent/EP1397124B1/fr not_active Expired - Lifetime
- 2002-06-19 DK DK02748965T patent/DK1397124T3/da active
2006
- 2006-12-04 CY CY20061101738T patent/CY1105822T1/el unknown

Also Published As

Publication number	Publication date
EP1397124B1 (fr)	2006-11-29
CY1105822T1 (el)	2011-02-02
DE60216453T2 (de)	2007-09-20
DE60216453D1 (de)	2007-01-11
ES2275889T3 (es)	2007-06-16
EP1397124A2 (fr)	2004-03-17
ATE346601T1 (de)	2006-12-15
WO2003003971A2 (fr)	2003-01-16
WO2003003971A3 (fr)	2003-12-04
AU2002319381A1 (en)	2003-01-21

Publication	Publication Date	Title
EP4549454A3 (en)	2025-07-09	Gip/glp1 co-agonist compounds
DK1349856T3 (da)	2005-10-17	Isoindolin-1-on-glucokinase-aktivatorer
WO2006000567A3 (en)	2006-06-22	Use of glp-1 receptor agonists and / or dpp-iv inhibitors in combination with proton pump inhibitors and ppar agonists for the preparation of a medicament for the treatment of diabetes type i i and impaired pancreatic beta-cell function
BRPI0606727A (pt)	2008-03-11	terapia de combinação para o tratamento de diabetes e condições relacionadas com ele e para o tratamento de condições melhoradas através de aumento no nìvel de glp-1 no sangue
DE602004026113D1 (de)	2010-04-29	Glp-1-verbindungen
DK1523325T3 (da)	2011-11-21	Fremgangsmåder og sammensætninger til behandling af polycystisk ovariesyndrom
BR112021020071A2 (pt)	2021-12-14	Compostos agonistas duplos do receptor de glp-1 e gip e uso dos mesmos
EP1671649A4 (en)	2007-05-02	MEANS FOR THE TREATMENT OF DIABETES
MY135222A (en)	2008-02-29	Substituted phenylacetamides and their use as glucokinase activators
ATE193541T1 (de)	2000-06-15	Insulinotropes hormon
TR200100079T2 (tr)	2001-06-21	Glikoza karşı ß-hücre tepkisini arttıran glukagon benzeri peptid-1
DE69942307D1 (de)	2010-06-10	N-terminal veränderte glp-1 abkömmlinge
BR0308904A (pt)	2005-05-03	Método de tratamento de gastroparesia, e, uso de um composto de glp-1
BRPI0413489B8 (pt)	2021-05-25	molécula de anticorpo anti-cd20 fusionada a il-2 e composição farmacêutica compreendendo a mesma
EP1551494A4 (en)	2010-07-07	MEDICAL INJECTOR WITH FRONT LOADING AND SYRINGES, SYRINGE INTERFACES, SYRINGE ADAPTERS AND CORRESPONDING SYRINGE PISTONS
BR0314655A (pt)	2005-08-02	Droga de combinação
AR008444A1 (es)	2000-01-19	Empleo de antagonistas de leptina para el tratamiento de la resistencia a la insulina en diabetes del tipo ii
SE0301882D0 (sv)	2003-06-25	New use I
TR199902980T2 (xx)	2000-05-22	Diabetin tedavisi i�in leptin antagonistlerinin kullan�m�.
DK1397124T3 (da)	2007-04-02	Anvendelse af diabetesmidler til fremstilling af et lægemiddel med helende virkning
CO2024012130A2 (es)	2024-09-30	Péptidos agonistas duales de glp-1 y glucagón con estabilidad biológica mejorada
EA202192296A1 (ru)	2022-01-21	Терапевтическое применение дулаглутида
ITRN20040042A1 (it)	2004-11-30	Garza chirurgica con matrice di identificazione
ATE377424T1 (de)	2007-11-15	Verwendung von silymarin und carbopol zur regenerierung von pankreasgewebe und -zellen mit durch diabetes mellitus beeinträchtigter endokriner sekretion
DE60114597D1 (de)	2005-12-08	Naphthamid-neurokinin antagonisten zur verwendung als medikamente